tirzepatide kidney disease 🧬 New data from the SUMMIT trial reveals that long-term (Zepbound) may significantly improve function in patients with obesity, chronic kidney (CKD), and heart failure with preserved ejection fraction ( New Cleveland Clinic research finds

Testing is typically limited to research settings or manufacturer-specific assays not routinely accessible to clinicians outside clinical trials

GLP-1 does not typically significantly affect mood or energy levels, but individual experiences can vary

Results For Study 4 At the end of the 36-week open-label ZEPBOUND lead-in period, of the 670 randomized patients, 93% were on ZEPBOUND MTD of 15 mg weekly and 7% were on MTD of 10 mg weekly

95% CI, 0.42 to 0.87

John used it for health reasons, Lisa for specific weight loss goals, Mark for ongoing weight management

White has received major media coverage by TV (NBC Nightly News, Good Morning America, Today Show, Dr Oz Show, BBC & CBC, PBS News Hour, CNN, MSNBC), newspaper (New York Times, Washington Post, Boston Globe, LA Times, Chicago Tribune), radio (WNPR, CBS Radio Network, Bloomberg Radio, SiriusXM, Colin McEnroe Show), and magazine/online (Vogue, The Scientist, Newsweek, The Conversation, Salon, Huffington Post, Inverse) media outlets among many others